SUVmax | ||||
Patient characteristic | No. of patients | Median | IQR | P |
Sex | ||||
Male | 22 | 45.9 | 36.3–58.2 | 0.875 |
Female | 21 | 37.8 | 35.7–69.3 | |
Syndrome | ||||
Yes | 8 | 33.9 | 19.8–95.6 | 1.000 |
No | 35 | 45.5 | 38.6–57.4 | |
Stage | ||||
IIIB | 7 | 34.3 | 25.2–62.2 | 0.687 |
IV | 36 | 48.9 | 39.9–62.1 | |
2010 WHO classification | ||||
NET G1 | 14 | 57.7 | 42.4–79.3 | 0.092 |
NET G2 | 29 | 36.2 | 33.2–55.7 | |
Ki-67 | ||||
≤5% | 22 | 53.3 | 42.5–68.6 | 0.132 |
>5% | 21 | 36.0 | 29.1–58.5 | |
Follow-up at 24 mo | ||||
Stable disease | 18 | 49.8 | 44.9–78.8 | 0.022 |
Progressive disease | 20 | 33.4 | 26.1–52.4 |